1 / 25

Optimizing management of chemotherapy-induced neutropenia: the development of once-per-cycle cytokine support

Filgrastim in the treatment of chemotherapy-induced neutropenia. Myelosuppression is a major dose-limiting adverse effect of chemotherapyFilgrastim reduces duration and severity of neutropenia and its sequelaeSerum half-life (~3 hours) and neutrophil response necessitate daily injections. The rel

dugan
Download Presentation

Optimizing management of chemotherapy-induced neutropenia: the development of once-per-cycle cytokine support

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Optimizing management of chemotherapy-induced neutropenia: the development of once-per-cycle cytokine support Salvatore Siena Divisione di Oncologia Medica Falck Ospedale Niguarda Ca’ Granda Department of Oncology and Hematology Milan, Italy

More Related